New findings from the ACTIV-6 Research Study, led by the DCRI in partnership with Vanderbilt University Medical Center, found no symptomatic or clinical benefit in taking montelukast for COVID-19. Read more about the study, which involved diverse participants from across the nation: dcri.org/news/study-con…

Check out the latest AJPH supplement on how RADx-UP focuses on community-engaged research, featuring DCRI's Emily D'Agostino as a guest editor!

For years, eggs have had a reputation as being bad for one’s cholesterol levels. Now, finding from PROSPERITY trial led by DCRI fellow Nina Nouhravesh shows the food had no negative impact on the cholesterol or heart-health for high-risk individuals: scitechdaily.com/new-research-s…

Join us in celebrating the latest DCRI professor promotions and tenure recipients! Kanecia Zimmerman and Christoph Hornik received promotions to full professors, while Robert Mentz, MD and Rachel Greenberg were granted tenure. medschool.duke.edu/blog/congratul…

DCRI Faculty members Aparna Swaminathan and Jamie Todd will be among those presenting new findings in pulmonary research at #ATS2024 . Check the images below for their session date and times, and be on the lookout for our conference highlights.

For Vidya Raghavan, DCRI Associate Director for Vendor Management, each day starts with a cup of coffee while planning out her day. Learn more about the great work Vidya and others across Duke engage in every day in this new piece from Working@Duke: stories.duke.edu/a-24-hour-work…

Congratulations to Adrian “WE NEED RCTS!” Hernandez, Kanecia Zimmerman, and Neha Pagidipati, who were among the recipients of this year’s Duke University School of Medicine faculty awards! See the full list of recipients here: medschool.duke.edu/news/school-me…

The DCRI is excited to announce the #PrecisionHealthAlliance , a new consortium co-founded by the DCRI, Beam Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, and Verve Therapeutics, to understand and address the challenges facing the field of precision health. Learn more: dcri.org/news/dcri-coll…

New findings show adding ertugliflozin to GDMT can can reduce the need for more invasive therapies, highlighting the importance of optimal GDMT. DCRI’s Steve Greene says this shows 'a major difference' between general GDMT and optimal GDMT.
tctmd.com/news/sglt2-inh…

After years of decline, a recent study lead by Marat Fudim, MD MHS has shown an alarming rise in heart failure mortality – especially among young adults. Learn more about the potential factors at play, and what could be done to help reverse this concerning trend: medschool.duke.edu/news/study-sho…

New weight loss drugs can be an effective tool for reducing CV-risks when combined with lifestyle changes, according to DCRI’s Neha Pagidipati. See what she had to say about incorporating these drugs as part of treatment plans at last month’s #ACC24 : dcri.org/news/acc-2024-…

Tomorrow is the start of the 2024 #ISPORannual event! DCRI PrefER presenters, panelists, discussants, and moderators include Juan Marcos Gonzalez, Reed Johnson, Shelby Reed, Alicja Mastylak, and Jessie Sutphin. Stay tuned for the full session schedule!

Hand grip strength (HGS) is an informative biomarker – yet its value outside of older adult populations is unexplored. DCRI’s Adam Goode and Verily examined how HGS can identify clinical characteristics and conditions in other demographic groups: nature.com/articles/s4159…

If you have #Afib , your doctor may recommend cardioversion treatment, which is “very much like rebooting a computer that has crashed,” says DCRI’s Jonathan Piccini, MD, MHS. Learn more about what he and other experts have to say about this treatment option: healthcentral.com/article/electr…

Dr. Stephen Balevic and colleagues at the DCRI recently conducted a secondary analysis of the ACTIV-1 IM clinical trial, finding reduced mortality in hospitalized adults with severe COVID-19 who achieved higher exposures of abatacept. Learn more: jamanetwork.com/journals/jaman…

The DCRI, together with Duke-Margolis and Eli Lilly and Company, is working to establish a platform for characterizing obesity management patterns and treatment responses while addressing barriers to clinical trials. Learn more: dcri.org/news/new-partn…